These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 35721972)
1. Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies. Hassan M; Yasir M; Shahzadi S; Kloczkowski A ACS Omega; 2022 Jun; 7(23):19243-19260. PubMed ID: 35721972 [TBL] [Abstract][Full Text] [Related]
2. The exploration of novel Alzheimer's therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches. Hassan M; Raza H; Abbasi MA; Moustafa AA; Seo SY Biomed Pharmacother; 2019 Jan; 109():2513-2526. PubMed ID: 30551512 [TBL] [Abstract][Full Text] [Related]
3. Exploration of Flavonoids as Lead Compounds against Ewing Sarcoma through Molecular Docking, Pharmacogenomics Analysis, and Molecular Dynamics Simulations. Yasir M; Park J; Han ET; Park WS; Han JH; Kwon YS; Lee HJ; Hassan M; Kloczkowski A; Chun W Molecules; 2023 Jan; 28(1):. PubMed ID: 36615603 [TBL] [Abstract][Full Text] [Related]
4. Computational prognostic evaluation of Alzheimer's drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches. Hassan M; Shahzadi S; Yasir M; Chun W; Kloczkowski A Sci Rep; 2023 Oct; 13(1):18022. PubMed ID: 37865690 [TBL] [Abstract][Full Text] [Related]
5. Investigation of Flavonoid Scaffolds as DAX1 Inhibitors against Ewing Sarcoma through Pharmacoinformatic and Dynamic Simulation Studies. Yasir M; Park J; Han ET; Park WS; Han JH; Kwon YS; Lee HJ; Hassan M; Kloczkowski A; Chun W Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298283 [TBL] [Abstract][Full Text] [Related]
6. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403 [TBL] [Abstract][Full Text] [Related]
8. Structure-based screening of FDA-approved drugs identifies potential histone deacetylase 3 repurposed inhibitor: molecular docking and molecular dynamic simulation approaches. Shamsi A; Khan MS; Yadav DK; Shahwan M Front Pharmacol; 2024; 15():1424175. PubMed ID: 39005934 [TBL] [Abstract][Full Text] [Related]
9. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381 [TBL] [Abstract][Full Text] [Related]
10. In Silico Study towards Repositioning of FDA-Approved Drug Candidates for Anticoronaviral Therapy: Molecular Docking, Molecular Dynamics and Binding Free Energy Calculations. Qayed WS; Ferreira RS; Silva JRA Molecules; 2022 Sep; 27(18):. PubMed ID: 36144718 [TBL] [Abstract][Full Text] [Related]
11. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Pessetto ZY; Chen B; Alturkmani H; Hyter S; Flynn CA; Baltezor M; Ma Y; Rosenthal HG; Neville KA; Weir SJ; Butte AJ; Godwin AK Oncotarget; 2017 Jan; 8(3):4079-4095. PubMed ID: 27863422 [TBL] [Abstract][Full Text] [Related]
12. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma. Yuan B; Ji W; Xia H; Li J Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472 [TBL] [Abstract][Full Text] [Related]
13. EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma. Sankar S; Gomez NC; Bell R; Patel M; Davis IJ; Lessnick SL; Luo W Genes Cancer; 2013 May; 4(5-6):213-23. PubMed ID: 24069508 [TBL] [Abstract][Full Text] [Related]
18. KDM5A and PHF2 positively control expression of pro-metastatic genes repressed by EWS/Fli1, and promote growth and metastatic properties in Ewing sarcoma. McCann TS; Parrish JK; Hsieh J; Sechler M; Sobral LM; Self C; Jones KL; Goodspeed A; Costello JC; Jedlicka P Oncotarget; 2020 Oct; 11(43):3818-3831. PubMed ID: 33196691 [TBL] [Abstract][Full Text] [Related]
19. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296 [TBL] [Abstract][Full Text] [Related]
20. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma. Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]